PDAC at ASCO 2026 / Pancreatic Cancer 06/15/2026

Doubling Survival: The Clinical Impact of RASolute 302

Close-up of a smiling male scientist in a checkered shirt and tie, outdoors, representing cancer research and medical innovation. Andrew H. Ko, MD Eileen O'Reilly, MD 1. Professional oncologist in a suit with a pink tie, focused on cancer research, healthcare, or medical leadership, representing expertise in oncology. Shubham Pant, MD, MBBS OncUpdates healthcare professional, expert in cancer research and treatment, providing latest updates on oncology therapies, clinical trials, and cancer patient care. Rachna Shroff, MD, MS, FASCO Smiling man with beard wearing a white shirt, professional headshot, suitable for oncology or cancer research content, emphasizing healthcare and medical expertise. Rahul Gosain, MD, MBA Oncologist smiling in white coat, highlighting cancer research and treatment expertise, with a bow tie, in a bright medical setting. Rohit Gosain, MD

Key Points

  • Median overall survival (OS) doubled from approximately 6.7 months to 13.2 months (hazard ratio, approximately 0.40).
  • The results showed improved progression-free survival (PFS), response rate, and quality-of-life (QOL) outcomes.
  • Benefit was observed across multiple KRAS mutation subtypes.
  • The findings suggest potential to treat broader real-world patient populations.

RASolute 302 demonstrated a clinically meaningful and statistically robust improvement in outcomes, with median OS increasing from approximately 6.7 months with chemotherapy to 13.2 months with daraxonrasib. The benefit was observed in both KRAS G12-mutant and intention-to-treat populations, with a hazard ratio of approximately 0.40. The panel, cohosted by Rahul Gosain, MD, MBA, and Rohit Gosain, MD, and featuring Andrew H. Ko, MD, of the University of California, San Francisco; Eileen O’Reilly, MD, of Memorial Sloan Kettering Cancer Center; Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center; and Rachna Shroff, MD, MS, FASCO, of the University of Arizona, continued the discussion on this topic. 

PFS and objective response rates also favored the investigational agent, with response rates approaching 30% versus approximately 11% with chemotherapy. Importantly, patient-reported outcomes suggested delayed deterioration in QOL, reinforcing that the benefit extended beyond radiographic or survival end points.

Subgroup analyses indicated consistent benefit across KRAS subtypes, including less common alterations such as G12R, G13, and Q61 mutations. Investigators also reported exploratory activity in patients without detectable KRAS mutations. Investigators emphasized that while further genomic refinement is needed, the signal appeared broadly applicable across molecular subsets.

Clinically, experts highlighted that daraxonrasib may expand treatment options for patients unable to tolerate further chemotherapy because of declining performance status, potentially increasing access to effective second-line therapy.